文献速递心境障碍

单盲安慰剂导入期与抗抑郁药随机临床试验中安慰剂反应的关联:系统综述与Meta分析

Association of Single-blind Placebo Run-in Periods With the Placebo Response in Randomized Clinical Trials of Antidepressants: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Psychiatry · 2022-01-01

该系统综述与Meta分析纳入347项双盲安慰剂对照抗抑郁药随机临床试验(共89183例受试者),其中50%报告使用单盲安慰剂导入期。使用导入期的研究安慰剂反应(g=1.05)小于未使用者(g=1.15),药物反应也较小,但药物-安慰剂差值无显著差异,提示导入期未提高试验敏感性。

要点

  • 使用安慰剂导入期的研究安慰剂反应g=1.05,小于未使用者的g=1.15(P=.02)。
  • 未使用导入期的研究药物反应g=1.55,大于使用者的g=1.42(P=.001)。
  • 药物-安慰剂差值及药物vs安慰剂反应似然比在有无导入期研究间无显著差异。

核心结论

  • 使用安慰剂导入期的随机临床试验在安慰剂组和药物组均产生较小的组内变化,效应量降低幅度相当,因此未观察到更大的药物-安慰剂差值,提示导入期未提高试验敏感性。
  • 作者认为,鉴于所需资源和可能的欺骗及对外部效度的风险,应终止在抗抑郁药随机临床试验中使用安慰剂导入期的做法。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase、Cochrane对照试验中心注册库、PsycINFO及未发表研究库,截至2021年7月。
  • 纳入成人抑郁障碍的双盲、安慰剂对照抗抑郁药随机临床试验,共347项试验(89183例受试者),174项(50%)报告使用单盲安慰剂导入期,189项研究有反应结局数据。
  • 采用随机效应Meta分析计算效应量(Hedges g),并用亚组分析比较使用与不使用安慰剂导入期的结局。

主要发现

  • 使用安慰剂导入期的研究安慰剂反应g=1.05(95%CI 0.98-1.11;I²=82%),小于未使用导入期的研究g=1.15(95%CI 1.09-1.21;I²=81%;P=.02)。
  • 未使用安慰剂导入期的研究药物反应g=1.55(95%CI 1.49-1.61;I²=85%),大于使用导入期的研究g=1.42(95%CI 1.36-1.48;I²=81%;P=.001)。
  • 药物-安慰剂差值在使用导入期的研究为g=0.33(95%CI 0.29-0.38;I²=47%),未使用者为g=0.34(95%CI 0.30-0.38;I²=54%),组间无显著差异(P=.92)。
  • 药物vs安慰剂反应似然比在使用导入期的研究为OR 1.89(95%CI 1.76-2.03),未使用者为OR 1.77(95%CI 1.65-1.89),组间无显著差异(P=.18)。

临床怎么用

  • 作者认为,应终止在抗抑郁药随机临床试验中使用安慰剂导入期的做法。

局限性

  • 使用安慰剂导入期的研究安慰剂反应I²=82%,未使用者I²=81%。
  • 未使用安慰剂导入期的研究药物反应I²=85%,使用导入期的研究I²=81%。
  • 药物-安慰剂差值在使用导入期的研究I²=47%,未使用者I²=54%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Single-blind placebo run-in (PRI) periods are common in randomized clinical trials (RCTs) of treatment for depression. They aim to increase sensitivity to detect drug effects; however, the association of PRI periods with study outcomes remains unclear. This is concerning given the costs of PRI periods to patients and investigators. OBJECTIVE: To examine the association of the use of PRI periods with the placebo response, drug response, and drug-placebo difference among RCTs of antidepressants. DATA SOURCES: MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and PsycINFO, as well as repositories of unpublished studies, were systematically searched up to July 2021. STUDY SELECTION: Included studies were double-blind, placebo-controlled RCTs of antidepressant medication among adults with depressive disorders. DATA EXTRACTION AND SYNTHESIS: Data were extracted into a coding sheet, including the characteristics of studies, the characteristics of PRI periods, and the outcomes of studies. MAIN OUTCOMES AND MEASURES: Study outcomes were the primary depression symptom measure reported by the RCT. These outcomes were used to calculate effect sizes (Hedges g) of the within-group drug response and placebo response as well as the drug-placebo difference. Random-effects meta-analysis was used to calculate effect sizes, and subgroup analyses were used to compare outcomes depending on use of PRI periods. RESULTS: A total of 347 trials (representing 89 183 participants) were included; 174 studies (50%) reported using a single-blind PRI period. Response outcome data were available for 189 studies. Studies using PRI periods reported a smaller placebo response (g = 1.05 [95% CI, 0.98-1.11]; I2 = 82%) than studies that did not use a PRI period (g = 1.15 [95% CI, 1.09-1.21]; I2 = 81%; P = .02). Subgroup analysis showed a larger drug response size among studies that did not use a PRI period (g = 1.55 [95% CI, 1.49-1.61]; I2 = 85%) than those that did use a PRI period (g = 1.42 [95% CI, 1.36-1.48]; I2 = 81%; P = .001). The drug-placebo difference did not differ by use of PRI periods (g = 0.33 [95% CI, 0.29-0.38]; I2 = 47% for use of a PRI period vs g = 0.34 [95% CI, 0.30-0.38]; I2 = 54% for no use of PRI periods; P = .92). The likelihood of response to drug vs placebo also did not differ between studies that used a PRI period (odds ratio, 1.89 [95% CI, 1.76-2.03]) and those that did not use a PRI period (odds ratio, 1.77 [95% CI, 1.65-1.89]; P = .18). CONCLUSIONS AND RELEVANCE: This study suggests that RCTs using PRI periods yield smaller within-group changes across both placebo and drug groups compared with RCTs without PRI periods. The reduction in effect size across groups was equivalent in magnitude. Consequently, PRI studies do not observe larger drug-placebo differences, suggesting that they do not increase trial sensitivity. As such, given the resources and probable deception required and risk to external validity, the practice of using PRI periods in RCTs of antidepressants should be ended.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Scott AJ, Sharpe L, Quinn V, et al. Association of Single-blind Placebo Run-in Periods With the Placebo Response in Randomized Clinical Trials of Antidepressants: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022. PMID: 34757405. doi:10.1001/jamapsychiatry.2021.3204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。